INCY
US EQUITY
Health Care
Biotechnology
CIK: 879169
Incyte (INCY) Quant Factor Diagnostic & Fair Value Model
Incyte (Ticker: INCY) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$115.71
-1.04%
Latest Close (2026-10-23)
Market Cap: $23.45B
P/E Ratio: 19.7
Momentum Strength
3M / 12M
-2.66%
1M: -7.02%
12M: +31.40%
Quality (ROE)
Point-in-Time
+21.58%
Trailing Return on Equity
Technical Trend
RSI 14
53.4
SMA50: $121.26
SMA200: $107.78
Valuation Multiplier
Trailing
19.7
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
INCY trades within a typical sector multiple band (19.7x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 7/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 879169 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-03-31 | 2026-04-28 | - | $303.33M | $369.35M | $1.47 |
| 10-Q | 2025-12-31 | 2026-04-28 | - | - | - | - |
| 10-Q | 2025-03-31 | 2026-04-28 | - | $158.20M | $266.07M | $0.80 |
| 10-K | 2025-12-31 | 2026-02-10 | - | $1.29B | $1.41B | $6.41 |
| 10-K | 2024-12-31 | 2026-02-10 | - | $32.62M | $335.34M | $0.15 |
| 10-K | 2023-12-31 | 2026-02-10 | - | $597.60M | $496.49M | $2.65 |
| 10-Q | 2025-09-30 | 2025-10-28 | - | $424.17M | $870.20M | $2.11 |
| 10-Q | 2025-06-30 | 2025-10-28 | - | $405.00M | $310.81M | $2.04 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Incyte (INCY) valuation multiples, momentum factors, and point-in-time filing conventions.
How should INCY's current valuation multiple be interpreted? ↓
INCY trades at a trailing P/E of 19.7x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are INCY's key momentum and technical factor indicators? ↓
As of the latest close, INCY shows a 1-month return of -7.02%, 3-month return of -2.66%, and 12-month return of +31.40%, with a 14-day RSI of 53.4. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for INCY? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can INCY be incorporated into systematic factor models? ↓
INCY can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.